Mirati Ther (MRTX)

Name: Mirati Ther (MRTX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Mirati Ther (MRTX)

Stock Card

$58.70

$0.00 (0.00%)

As on 23-Jan-2024 09:30EDT

Market cap

$4,118 Mln

Revenue (TTM)

$38 Mln

P/E Ratio

P/B Ratio

4.4

Div. Yield

0 %

Mirati Ther (MRTX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 58.70 High: 58.70

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-564 Mln
ROE

-0.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-4.1
Debt to Equity

0
Book Value

$--
EPS

$-12.1
Face value

--
Shares outstanding

70,147,696

10 Years Aggregate

CFO

$-1,694.36 Mln

EBITDA

$-2,287.60 Mln

Net Profit

$-2,305.78 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Mirati Ther (MRTX)	-0.1	-0.4	5.4	28.6	-35.1	-1.7	10.6
BSE Sensex^*	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 23-Jan-2024 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2023	2022	2021	2020	2019	2018	2017
Mirati Ther (MRTX)	29.7	-69.1	-33.2	70.4	203.8	131.4	284.2
S&P Small-Cap 600	13.9	-17.4	25.3	9.6	20.9	-9.7	11.7
BSE Sensex	18.7	4.4	22.0	15.8	14.4	5.9	27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Mirati Ther (MRTX)

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult... patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California. Read more

Founder, President, CEO & Director

Dr. Charles M. Baum M.D., Ph.D.
Founder, President, CEO & Director

Dr. Charles M. Baum M.D., Ph.D.
Headquarters

San Diego, CA
Website

https://www.mirati.com

FAQs for Mirati Ther (MRTX)

What is the current share price of Mirati Ther (MRTX) Today?

The share price of Mirati Ther (MRTX) is $58.70 (NASDAQ) as of 23-Jan-2024 09:30 EDT. Mirati Ther (MRTX) has given a return of -35.07% in the last 3 years.

What is the current PB & PE ratio of Mirati Ther (MRTX)?

Since, TTM earnings of Mirati Ther (MRTX) is negative, P/E ratio is not available.
The P/B ratio of Mirati Ther (MRTX) is 4.35 times as on 23-Jan-2024, a 16 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.